

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following drug types best describes the mechanism of action of the oral novel agent amcenestrant (SAR439859)?
  - Anti-PD-1/PD-L1 monoclonal antibody
  - CDK4/6 inhibitor
  - PI3K inhibitor
  - SERD (selective estrogen receptor degrader)
- Recent results from the Phase III DESTINY-Breast03 trial evaluating T-DM1 versus trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane included which hazard ratio for progression-free survival (PFS) at 12 months?
  - 0.88
  - 0.68
  - 0.48
  - 0.28
- The EMPOWER-Lung 1 study of patients with a PD-L1 tumor proportion score of at least 50% showed an increase in OS with which agent combined with chemotherapy versus placebo with chemotherapy?
  - Durvalumab
  - Cemiplimab
  - Osimertinib
  - Pembrolizumab
- Early results from the Phase III POSEIDON trial evaluating the addition of durvalumab with or without tremelimumab to platinum-based chemotherapy for patients with previously untreated metastatic NSCLC included an improvement in PFS on which study arm in comparison to chemotherapy alone?
  - Durvalumab with tremelimumab and chemotherapy
  - Durvalumab with chemotherapy
  - Both experimental arms
- Results from the Phase II TASC01 trial evaluating TAS-102 and capecitabine in combination with bevacizumab as first-line treatment for patients with metastatic colorectal cancer who are not eligible for intensive therapy showed which of the following?
  - Improvement in progression-free survival (PFS)
  - Improvement in overall survival (OS)
  - Improvement in both PFS and OS
  - No improvement in PFS or OS
- In the pivotal CheckMate 274 study, which patient population experienced an improvement in disease-free survival with adjuvant nivolumab compared to placebo?
  - Intention to treat
  - Patients with PD-L1  $\geq 1\%$
  - Both a and b
  - None of the above
- Which of the following CD19 CAR T-cell therapies is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy?
  - Tisagenlecleucel
  - Axicabtagene ciloleucel
  - Lisocabtagene maraleucel
  - Both a and b
  - Both b and c
  - Both a and c
  - All of a, b and c

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

8. Which of the following CAR T-cell therapies is approved for patients with relapsed or refractory mantle cell lymphoma?
- a. Axicabtagene ciloleucel
  - b. Brexucabtagene autoleucel
  - c. Tisagenlecleucel
  - d. Both a and b
  - e. Both b and c
  - f. Both a and c
  - g. All of a, b and c
9. Which of the following statements is true regarding the updated analysis of the GRIFFIN trial evaluating the addition of daratumumab to lenalidomide, bortezomib and dexamethasone for patients with newly diagnosed multiple myeloma who were transplant eligible?
- a. No improvement in stringent complete response rate was observed with daratumumab
  - b. Response rates and depths were better with daratumumab at all time points
  - c. The best response rates with daratumumab were at end of induction
  - d. None of the above
10. Which of the following drug types best describes the mechanism of action of the novel investigational agent sabatolimab (MBG453), which was recently granted an FDA fast track designation for myelodysplastic syndromes?
- a. BCL2 inhibitor
  - b. IDH1/2 inhibitor
  - c. FLT3 inhibitor
  - d. TIM-3 inhibitor